Merck & Company share price logo

Merck & Company

NYSE: MRK

$147.27

+2.36

(+1.63%)

Live

as on

Merck & Company Stock Performance

as on September 18, 2026 at 6:13 am IST

  • Day's Low

    Day's High

    $145.27
    $147.40
    downward going graph

    1.36%

    Downside

    0.09%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $77.58
    $156.92
    downward going graph

    47.32%

    Downside

    6.55%

    Upside

    downward going graph

Merck & Company share price movements today

Previous Close
$144.91
Open
$145.27
Volume
3.8M
Market Cap
$357.4B
Dividend Yield
2.36%
Day's Low - High
$145.27 - $147.40
52 Week Low - High
$77.58 - $156.92

Merck & Company Historical Returns

1 Month Return
+ 6.57 %
3 Month Return
+ 25.53 %
1 Year Return
+ 78.59 %
3 Year Return
+ 34.77 %
5 Year Return
+ 102.16 %

Merck & Company Stock Fundamentals & Key Indicators

Check Merck & Company market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$357.4B

EPS (TTM)

2.7452

Dividend Yield

2.36%

Quarterly Earnings Growth YOY

-0.19%

PE Ratio (TTM)

115.96

Industry PE ratio

25.75

PEG Ratio

2.6457

EBITDA

28.9B

Revenue (TTM)

66.6B

Profit Margin

4.77%

Return On Equity TTM

6.96%

Merck & Company Stock Valuation

Track how Merck & Company P/E has moved over time to understand its valuation trends.

Merck & Company in the last 5 years

  • Overview

  • Trends

Lowest (9.52x)

September 30, 2025

Industry (25.75x)

September 17, 2026

Today (115.96x)

September 17, 2026

Highest (69.20x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 115.96x

Merck & Company vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Merck & Company with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$357.4B102.16%115.964.77%2.36%
BUY$1.1T394.49%38.0483.40%0.59%
BUY$462.6B143.67%74.171.48%2.60%
BUY$641.8B62.23%30.8967.91%1.98%
BUY$253.9B46.59%24.3379.27%2.00%

Stock Returns calculator for Merck & Company Stock including INR - Dollar returns

The Merck & Company stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Merck & Company investment value today

Current value as on today

₹1,98,120

Returns

₹98,120

(+98.12%)

Returns from Merck & Company Stock

₹81,501 (+81.5%)

Dollar Impact

₹16,619 (+16.62%)

Analyst Recommendation on Merck & Company Stock

Based on 19 analysts

BUY

73.68%

Buy

26.32%

Hold

0.00%

Sell

Based on 19 analysts, 73.68421052631578% of analysts recommend a 'BUY' rating for Merck & Company. Average target price of $152.96

Merck & Company Share Price Target

Get share price movements and forecasts by analysts on Merck & Company.

What analysts predicted

3.72%UPSIDE

Target Price

$152.96

Current Price

$147.27

Analyzed by

19 Analysts

Target

$152.96

Merck & Company target price $152.96, a slight upside of 3.72% compared to current price of $147.27. According to 19 analysts rating.

Indian Investors' Interest in Merck & Company Stock

Investment in Merck & Company Shares on INDmoney has grown by 110.06% in the last 30 days, indicating increased investment activity.

Time period: to

Change:110.06% versus previous 30 day period

Search interest for Merck & Company Stock has increased by 130% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:130% versus previous 30 day period

Merck & Company Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
15,775
16,112
16,657
15,624
15,619
15,800
17,183
16,324
16,286
16,607
Gross Profit
12,235
12,367
12,577
11,796
11,734
11,953
12,989
11,507
13,342
12,212
Operating Income
5,760
6,128
3,984
4,348
6,710
6,359
7,463
6,160
-1,884
-683
EBITDA
6,744
7,448
5,606
5,695
7,315
6,360
8,144
6,297
-2,022
1,425
Interest Expense
303
310
330
328
313
305
327
411
479
525
Depreciation
984
1,132
1,186
1,197
1,099
1,119
1,154
2,466
1,512
1,583
Income Before Tax
5,670
6,006
4,090
4,170
5,903
4,999
6,745
3,420
-3,534
-683
Income Tax Expense
-
545
929
426
818
571
958
458
709
654
Net Income
4,762
5,455
3,157
3,743
5,079
4,427
5,785
2,963
-4,240
-1,335
Net Profit Margin
30.19%
33.86%
18.95%
23.96%
32.52%
28.02%
33.67%
18.15%
-26.03%
-8.04%

Merck & Company Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
39,807
40,122
42,294
39,121
41,518
48,704
59,283
60,115
64,168
64,926
Gross Profit
25,777
27,210
28,785
27,105
27,900
35,078
41,872
43,989
48,975
46,731
Operating Income
5,499
6,797
8,931
7,926
5,548
13,199
18,282
2,954
20,221
23,486
EBITDA
10,823
11,951
13,992
11,374
10,180
17,899
21,315
6,907
25,706
28,262
Interest Expense
693
754
772
893
831
806
962
1,146
1,271
1,357
Depreciation
-
4,637
4,519
3,652
3,625
3,214
3,909
3,800
4,499
5,838
Income Before Tax
4,659
6,521
8,701
7,171
5,863
13,879
16,444
1,889
19,936
21,067
Income Tax Expense
718
4,103
2,508
1,565
1,340
1,521
1,918
1,512
2,803
2,804
Net Income
3,920
2,394
6,220
9,843
7,067
13,049
14,519
365
17,117
18,254
Net Profit Margin
9.85%
5.97%
14.71%
25.16%
17.02%
26.79%
24.49%
0.61%
26.68%
28.12%

Merck & Company Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
5,461
3,161
3,744
5,085
4,429
5,787
2,963
-4,243
-1,337
Operating Cash Flow
5,637
9,291
3,450
2,500
3,293
7,822
2,857
3,918
5,370
Investing Cash Flow
-1,069
-3,845
-1,444
-1,487
-770
-283
-11,201
-10,210
-5,602
Financing Cash Flow
1,216
-2,425
-3,009
-5,755
-3,556
2,638
4,751
-2,981
1,762
Change in Cash
5,702
3,315
-1,370
-4,586
-659
10,187
-3,514
-9,292
1,493

Merck & Company Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,418
6,193
9,777
7,082
12,358
14,526
365
17,133
18,254
Operating Cash Flow
6,447
10,922
13,440
10,253
14,109
19,095
13,006
21,468
16,472
Investing Cash Flow
2,679
4,314
-2,629
-9,443
-16,555
-4,960
-14,083
-7,734
-13,741
Financing Cash Flow
-10,006
-13,160
-8,861
-2,832
2,593
-9,119
-4,810
-7,032
-1,922
Change in Cash
-423
1,871
1,967
-1,769
14
4,606
-5,864
6,409
1,372

Mutual Funds that own Merck & Company Stock

Check out the Mutual Funds with significant holdings in Merck & Company.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
6.783557%
167362009
Fidelity Concord Street Trust
1.71812%
42388972
VANGUARD SPECIALIZED FUNDS
1.629282%
40197185
JPMorgan Trust II
0.681493%
16813621
VANGUARD INSTITUTIONAL INDEX FUNDS
0.615527%
15186129

Global Institutional Holdings in Merck & Company

Funds
Holdings
Vanguard
8.95%
iShares
5.29%
SPDR
4.2%
Schwab
1.78%
Ken Fisher
1.56%

Merck & Company News & Key Events

  • img

    Today's Timeline - 14 September

    Mon, 03:50 PM

    -

    Perspective Therapeutics announces clinical collaboration with Merck to evaluate PSV359 in combination with Keytruda for certain cancers.

    Tue, 02:32 AM

    -

    Merck CEO highlights pipeline progress and strong Animal Health performance, expecting significant revenue growth by mid-2030s.

Insights on Merck & Company

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Merck & Co., Inc. has shown positive revenue growth over the last two quarters. The revenue increased from $16.28 billion to $16.60 billion, reflecting an average increase of 1.9% per quarter.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Merck & Co., Inc. has shown a positive trend in its net profit over the last two quarters. The company's net profit improved from -4.24 billion dollars to -1.33 billion dollars, reflecting an average increase of 217.6% each quarter.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, MRK has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MRK has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, MRK stock has moved up by 25.5%

About Merck & Company

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
OrganisationMerck & Company
Headquarters126 East Lincoln Avenue, Rahway, NJ, United States, 07065
IndustryDrug Manufacturers - General
CEOMr. Robert M. Davis J.D.
E-voting on sharesClick here to vote

Key Management of Merck & Company

Name

Title

Ms. Betty D. Larson

Executive VP & Chief Human Resources Officer

Mr. Robert M. Davis J.D.

Chairman, President & CEO

Dr. Dean Y. Li M.D., Ph.D.

Executive VP & President of Merck Research Laboratories

Mr. Dalton E. Smart III

Senior VP of Finance, Principal Accounting Officer & Global Controller

Mr. Peter Dannenbaum

Vice President of Investor Relations

Mr. Chirfi Guindo

Executive Vice President of Strategic Access, Policy & Communications

Ms. Caroline A. Litchfield

Executive VP & CFO

Ms. Jennifer L. Zachary J.D.

Executive VP & General Counsel

Mr. Gaurav K. Gupta

Executive Vice President and Chief Information & Digital Officer

Mr. Richard R. DeLuca Jr.

Executive VP & President of Merck Animal Health

FAQs

What is Merck & Company share price today?

Merck & Company share price today is $147.27 as on . Merck & Company share today touched a day high of $147.40 and a low of $145.27.

What is the 52 week high and 52 week low for Merck & Company share?

Merck & Company share touched a 52 week high of $156.92 on and a 52 week low of $77.58 on . Merck & Company stock price today i.e. is trending at $147.27,which is 6.15% down from its 52 week high and 89.83% up from its 52 week low.

What is Merck & Company's market capitalisation today?

Merck & Company market capitalisation is $0.36T as on .

How to invest in Merck & Company Stock (MRK) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Merck & Company on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merck & Company Shares that will get you 0.0102 shares as per Merck & Company share price of $147.27 per share as on September 18, 2026 at 12:43 am IST.

What is the minimum amount required to buy Merck & Company Stock (MRK) from India?

Indian investors can start investing in Merck & Company (MRK) shares with as little as ₹95.93 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹959.30 in Merck & Company stock (as per the Rupee-Dollar exchange rate as on ). Based on Merck & Company share’s latest price of $147.27 as on September 18, 2026 at 12:43 am IST, you will get 0.0679 shares of Merck & Company. Learn more about fractional shares .

What are the returns that Merck & Company has given to Indian investors in the last 5 years?

Merck & Company stock has given 102.16% share price returns and 29.9% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?